Compare ABAT & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABAT | SIGA |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.9M | 462.6M |
| IPO Year | N/A | 1997 |
| Metric | ABAT | SIGA |
|---|---|---|
| Price | $3.98 | $6.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 327.3K |
| Earning Date | 02-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | ★ 9.57% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | $5,025,853.00 | ★ $172,249,641.00 |
| Revenue This Year | $145.40 | N/A |
| Revenue Next Year | N/A | $132.36 |
| P/E Ratio | ★ N/A | $6.09 |
| Revenue Growth | ★ 821.40 | N/A |
| 52 Week Low | $0.86 | $4.95 |
| 52 Week High | $11.49 | $9.62 |
| Indicator | ABAT | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 44.44 |
| Support Level | $3.61 | $6.20 |
| Resistance Level | $4.43 | $6.45 |
| Average True Range (ATR) | 0.38 | 0.17 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 42.35 | 33.73 |
American Battery Technology Co is an integrated critical battery minerals company that develops technologies for both primary battery minerals manufacturing and lithium-ion battery recycling. It operates battery recycling facilities that process materials from electric vehicle batteries, stationary battery energy storage systems, and consumer electronics. Additionally, the company advances lithium production projects using proprietary technology to produce battery-grade lithium hydroxide. It generates revenue mainly from its recycling operations and is expanding capacity with strategic partnerships and government grants. The company's activities focus on creating a closed-loop battery materials supply chain to support sustainable manufacturing in the United States.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.